GlucoTrack, Inc. Logo

GlucoTrack, Inc.

GCTK

(1.2)
Stock Price

0,29 USD

-1250.82% ROA

1630.05% ROE

-1.55x PER

Market Cap.

11.786.864,00 USD

-6.93% DER

0% Yield

-35511.9% NPM

GlucoTrack, Inc. Stock Analysis

GlucoTrack, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

GlucoTrack, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.43x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

Negative ROE (-164.92%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-52.05%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

GlucoTrack, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

GlucoTrack, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

GlucoTrack, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

GlucoTrack, Inc. Revenue
Year Revenue Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 59.775 100%
2015 143.167 58.25%
2016 611.689 76.59%
2017 589.462 -3.77%
2018 43.488 -1255.46%
2019 208.762 79.17%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

GlucoTrack, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2009 1.005.108
2010 934.056 -7.61%
2011 1.789.301 47.8%
2012 1.920.690 6.84%
2013 1.986.754 3.33%
2014 1.849.624 -7.41%
2015 2.268.345 18.46%
2016 2.881.817 21.29%
2017 3.207.466 10.15%
2018 3.032.863 -5.76%
2019 1.605.631 -88.89%
2020 1.532.000 -4.81%
2021 1.810.000 15.36%
2022 1.967.000 7.98%
2023 6.772.000 70.95%
2023 4.704.000 -43.96%
2024 14.356.000 67.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

GlucoTrack, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 165.156
2010 457.495 63.9%
2011 544.145 15.92%
2012 852.908 36.2%
2013 1.041.140 18.08%
2014 1.546.664 32.68%
2015 2.488.995 37.86%
2016 3.234.022 23.04%
2017 7.764.905 58.35%
2018 3.475.305 -123.43%
2019 2.037.442 -70.57%
2020 1.142.000 -78.41%
2021 1.981.000 42.35%
2022 2.454.000 19.27%
2023 2.124.000 -15.54%
2023 2.278.000 6.76%
2024 3.208.000 28.99%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

GlucoTrack, Inc. EBITDA
Year EBITDA Growth
2009 -1.170.264
2010 -1.371.486 14.67%
2011 -2.310.401 40.64%
2012 -2.740.156 15.68%
2013 -2.994.210 8.48%
2014 -3.572.676 16.19%
2015 -5.892.295 39.37%
2016 -5.595.629 -5.3%
2017 -10.511.007 46.76%
2018 -6.478.884 -62.23%
2019 -3.462.590 -87.11%
2020 -3.085.000 -12.24%
2021 -3.880.000 20.49%
2022 -4.409.000 12%
2023 8.892.000 149.58%
2023 -7.091.000 225.4%
2024 -17.932.000 60.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

GlucoTrack, Inc. Gross Profit
Year Gross Profit Growth
2009 0
2010 0 0%
2011 0 0%
2012 -48 100%
2013 -62.484 99.92%
2014 -6.200 -907.81%
2015 98.276 106.31%
2016 552.105 82.2%
2017 449.253 -22.89%
2018 -52.075 962.7%
2019 157.762 133.01%
2020 -47.000 435.66%
2021 -42.000 -11.9%
2022 -23.000 -82.61%
2023 0 0%
2023 -13.000 100%
2024 -32.000 59.38%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

GlucoTrack, Inc. Net Profit
Year Net Profit Growth
2009 -1.202.296
2010 -2.788.446 56.88%
2011 -2.364.339 -17.94%
2012 -2.772.307 14.72%
2013 -9.796.853 71.7%
2014 2.980.426 428.71%
2015 -5.842.172 151.02%
2016 -5.409.737 -7.99%
2017 -10.328.806 47.62%
2018 -6.715.420 -53.81%
2019 -3.516.189 -90.99%
2020 -2.598.000 -35.34%
2021 -4.100.000 36.63%
2022 -4.438.000 7.62%
2023 8.892.000 149.91%
2023 -7.952.000 211.82%
2024 -17.956.000 55.71%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

GlucoTrack, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 -4
2010 -9 62.5%
2011 -6 -33.33%
2012 -7 0%
2013 -24 73.91%
2014 5 675%
2015 -14 130.77%
2016 -12 -8.33%
2017 -21 42.86%
2018 -10 -110%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -2 100%
2024 -3 66.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

GlucoTrack, Inc. Free Cashflow
Year Free Cashflow Growth
2010 -1.376.562
2011 -1.970.732 30.15%
2012 -2.308.336 14.63%
2013 -3.282.019 29.67%
2014 -3.425.100 4.18%
2015 -4.708.960 27.26%
2016 -5.388.285 12.61%
2017 -5.914.586 8.9%
2018 -4.897.648 -20.76%
2019 -3.922.519 -24.86%
2020 -3.554.000 -10.37%
2021 -3.774.000 5.83%
2022 -3.730.000 -1.18%
2023 -6.558.000 43.12%
2023 -1.880.000 -248.83%
2024 -1.919.000 2.03%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

GlucoTrack, Inc. Operating Cashflow
Year Operating Cashflow Growth
2010 -1.367.837
2011 -1.916.113 28.61%
2012 -2.296.989 16.58%
2013 -3.217.767 28.62%
2014 -3.361.645 4.28%
2015 -4.565.224 26.36%
2016 -5.311.830 14.06%
2017 -5.895.119 9.89%
2018 -4.892.277 -20.5%
2019 -3.899.087 -25.47%
2020 -3.501.000 -11.37%
2021 -3.769.000 7.11%
2022 -3.729.000 -1.07%
2023 -6.558.000 43.14%
2023 -1.880.000 -248.83%
2024 -1.907.000 1.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

GlucoTrack, Inc. Capital Expenditure
Year Capital Expenditure Growth
2010 8.725
2011 54.619 84.03%
2012 11.347 -381.35%
2013 64.252 82.34%
2014 63.455 -1.26%
2015 143.736 55.85%
2016 76.455 -88%
2017 19.467 -292.74%
2018 5.371 -262.45%
2019 23.432 77.08%
2020 53.000 55.79%
2021 5.000 -960%
2022 1.000 -400%
2023 0 0%
2023 0 0%
2024 12.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

GlucoTrack, Inc. Equity
Year Equity Growth
2011 968.239
2012 -503.069 292.47%
2013 -11.063.118 95.45%
2014 -4.832.203 -128.95%
2015 -6.970.914 30.68%
2016 -10.949.430 36.34%
2017 -16.574.933 33.94%
2018 -2.873.301 -476.86%
2019 -1.411.602 -103.55%
2020 8.982.000 115.72%
2021 5.155.000 -74.24%
2022 1.230.000 -319.11%
2023 3.197.000 61.53%
2023 5.557.000 42.47%
2024 -3.289.000 268.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

GlucoTrack, Inc. Assets
Year Assets Growth
2011 2.182.499
2012 814.571 -167.93%
2013 2.756.205 70.45%
2014 6.348.266 56.58%
2015 2.132.660 -197.67%
2016 2.460.946 13.34%
2017 1.668.928 -47.46%
2018 688.186 -142.51%
2019 1.282.461 46.34%
2020 10.606.000 87.91%
2021 6.265.000 -69.29%
2022 2.438.000 -156.97%
2023 4.905.000 50.3%
2023 7.195.000 31.83%
2024 608.000 -1083.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

GlucoTrack, Inc. Liabilities
Year Liabilities Growth
2011 1.214.260
2012 1.317.640 7.85%
2013 13.819.323 90.47%
2014 11.180.469 -23.6%
2015 9.103.574 -22.81%
2016 13.410.376 32.12%
2017 18.243.861 26.49%
2018 3.561.487 -412.25%
2019 2.694.063 -32.2%
2020 1.624.000 -65.89%
2021 1.110.000 -46.31%
2022 1.208.000 8.11%
2023 1.708.000 29.27%
2023 1.638.000 -4.27%
2024 3.897.000 57.97%

GlucoTrack, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-1.39
Price to Earning Ratio
-1.55x
Price To Sales Ratio
280.64x
POCF Ratio
-1.29
PFCF Ratio
-1.28
Price to Book Ratio
-3.58
EV to Sales
283.38
EV Over EBITDA
-1.56
EV to Operating CashFlow
-1.3
EV to FreeCashFlow
-1.29
Earnings Yield
-0.65
FreeCashFlow Yield
-0.78
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
4.33
Graham NetNet
-0.68

Income Statement Metrics

Net Income per Share
-1.39
Income Quality
0.76
ROE
-5.14
Return On Assets
-18.06
Return On Capital Employed
1.75
Net Income per EBT
1
EBT Per Ebit
2.26
Ebit per Revenue
-157.33
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
62.29
Research & Developement to Revenue
218.38
Stock Based Compensation to Revenue
6.67
Gross Profit Margin
0.21
Operating Profit Margin
-157.33
Pretax Profit Margin
-355.12
Net Profit Margin
-355.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.67
Free CashFlow per Share
-1.68
Capex to Operating CashFlow
-0.01
Capex to Revenue
1.69
Capex to Depreciation
3.94
Return on Invested Capital
2.48
Return on Tangible Assets
-12.51
Days Sales Outstanding
0
Days Payables Outstanding
21247.66
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.02
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
0,03
Book Value per Share
-0,60
Tangible Book Value per Share
-0.6
Shareholders Equity per Share
-0.6
Interest Debt per Share
0.04
Debt to Equity
-0.07
Debt to Assets
0.38
Net Debt to EBITDA
-0.02
Current Ratio
0.12
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-3061000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

GlucoTrack, Inc. Dividends
Year Dividends Growth

GlucoTrack, Inc. Profile

About GlucoTrack, Inc.

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

CEO
Mr. Paul V. Goode Ph.D.
Employee
6
Address
8 Ariel Sharon Street
Or Yehuda, 7760049

GlucoTrack, Inc. Executives & BODs

GlucoTrack, Inc. Executives & BODs
# Name Age
1 Mr. Mark Tapsak Ph.D.
Vice President of Technology
70
2 Mr. Paul V. Goode Ph.D.
Chief Executive Officer, President & Director
70
3 Ms. Drinda Benjamin
Vice President of Marketing
70
4 Mr. James S. Cardwell
Chief Financial Officer
70
5 Mr. Avner Gal MBA, MSc.EE
Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board
70
6 Mr. David Malka BA
Co-Founder
70
7 Mr. James P. Thrower Ph.D.
Vice President of Engineering
70

GlucoTrack, Inc. Competitors